Related Experiment Videos

Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients?

Stefan Arsov1, Reindert Graaff, Aurora M Morariu

  • 1Department of Biomedical Engineering, University of Groningen, Groningen, The Netherlands.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|November 26, 2009
PubMed

Insights

Hepatitis C did not increase advanced glycation end product (AGE) accumulation in hemodialysis patients. AGEs were higher in hemodialysis patients overall, influenced by age, diabetes, cardiovascular disease, and dialysis vintage, not hepatitis C status.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Hepatology

Background:

  • Hepatitis C infection may elevate oxidative stress, contributing to advanced glycation end product (AGE) accumulation and increasing cardiovascular disease (CVD) risk.
  • This study investigates the impact of Hepatitis C Virus (HCV) on AGE accumulation in patients undergoing hemodialysis (HD).

Purpose of the Study:

  • To determine if Hepatitis C influences the accumulation of advanced glycation end products (AGEs) in patients on hemodialysis.
  • To compare AGE levels in hemodialysis patients with and without Hepatitis C.

Main Methods:

  • Advanced glycation end product (AGE) accumulation was quantified using skin autofluorescence (AF).
  • The study included 92 hemodialysis patients (categorized as HCV+ or HCV-) and 93 healthy controls.
  • Biochemical markers related to cardiovascular disease (CVD) were measured in hemodialysis patients.

Main Results:

  • Hemodialysis patients exhibited significantly higher skin autofluorescence (AF) for AGEs compared to healthy controls.
  • AGE accumulation in hemodialysis patients was independently associated with age, diabetes mellitus (DM), CVD, and hemodialysis vintage.
  • Despite elevated liver enzymes and intercellular adhesion molecule 1 in HCV+ patients, skin AF and oxidative stress markers did not significantly differ between HCV+ and HCV- hemodialysis groups.

Conclusions:

  • Advanced glycation end product (AGE) accumulation is elevated in hemodialysis patients compared to healthy individuals.
  • Hepatitis C status (HCV+ vs. HCV-) did not significantly impact AGE accumulation in this hemodialysis population.
  • Cardiovascular disease, diabetes mellitus, age, and hemodialysis vintage are key independent predictors of AGE accumulation, whereas Hepatitis C is not.
Abstract

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...